Literature DB >> 11711386

Treatment of chronic hepatitis C.

G L Davis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11711386      PMCID： PMC1121632          DOI： 10.1136/bmj.323.7322.1141

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  Peginterferon alfa-2a in patients with chronic hepatitis C.

Authors:  S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

2.  A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

Authors:  K L Lindsay; C Trepo; T Heintges; M L Shiffman; S C Gordon; J C Hoefs; E R Schiff; Z D Goodman; M Laughlin; R Yao; J K Albrecht
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

3.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

4.  Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.

Authors:  L L Kjaergard; K Krogsgaard; C Gluud
Journal:  BMJ       Date:  2001-11-17

5.  Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

Authors:  T Poynard; J McHutchison; G L Davis; R Esteban-Mur; Z Goodman; P Bedossa; J Albrecht
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

Review 6.  Current therapy for chronic hepatitis C.

Authors:  G L Davis
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

7.  Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon.

Authors:  P Marcellin; N Boyer; C Degott; M Martinot-Peignoux; V Duchatelle; E Giostra; J Areias; S Erlinger; J P Benhamou
Journal:  Liver       Date:  1994-12

8.  Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration.

Authors:  T Poynard; V Leroy; M Cohard; T Thevenot; P Mathurin; P Opolon; J P Zarski
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

9.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245
  10 in total
  7 in total

Review 1.  Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.

Authors:  Gillian M Keating; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yvette Leung; Stefan J Urbanski; Lynn Schindel; Robert P Myers
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

3.  Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.

Authors:  Michael-R Kraus; Arne Schäfer; Herbert Csef; Michael Scheurlen
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

Review 4.  Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Gillian M Keating; Monique P Curran
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Selenium, Selenoproteins and Viral Infection.

Authors:  Olivia M Guillin; Caroline Vindry; Théophile Ohlmann; Laurent Chavatte
Journal:  Nutrients       Date:  2019-09-04       Impact factor: 5.717

6.  Does anybody read "evidence-based" articles?

Authors:  Yoon K Loke; Sheena Derry
Journal:  BMC Med Res Methodol       Date:  2003-07-31       Impact factor: 4.615

Review 7.  RNA Viruses: ROS-Mediated Cell Death.

Authors:  Mohammad Latif Reshi; Yi-Che Su; Jiann-Ruey Hong
Journal:  Int J Cell Biol       Date:  2014-05-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.